Blueprint Medicines's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Blueprint Medicines (NASDAQ:BPMC) is set to release its latest quarterly earnings report on October 26, 2023. Analysts estimate an earnings per share (EPS) of $-2.37. The company's past performance shows a pattern of share price drops following earnings reports, even when beating estimates. Shares are currently trading at $46.23, down 9.16% over the last 52-week period.
October 25, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Blueprint Medicines is expected to report an EPS of $-2.37 in its upcoming earnings. The company's stock has historically dropped following earnings reports, even when beating estimates. The stock is currently down 9.16% over the last 52 weeks.
The upcoming earnings report is highly relevant to BPMC's stock price. Given the historical trend of share price drops following earnings reports, even when beating estimates, there's a high likelihood of a negative short-term impact on the stock. The stock's current downtrend over the last 52 weeks further supports this analysis.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100